Shares of AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $19.03 and last traded at $18.89, with a volume of 457510 shares trading hands. The stock had previously closed at $18.97.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th.
Check Out Our Latest Analysis on AXGN
AxoGen Stock Down 1.0 %
The firm has a market cap of $822.99 million, a P/E ratio of -58.44 and a beta of 1.01. The firm's 50-day moving average price is $15.53 and its 200 day moving average price is $13.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.
Hedge Funds Weigh In On AxoGen
A number of large investors have recently bought and sold shares of AXGN. Quest Partners LLC boosted its position in shares of AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock worth $29,000 after buying an additional 2,076 shares during the period. R Squared Ltd acquired a new position in AxoGen during the 4th quarter worth $30,000. nVerses Capital LLC bought a new position in shares of AxoGen in the third quarter worth $56,000. Oppenheimer & Co. Inc. acquired a new position in shares of AxoGen during the third quarter valued at $156,000. Finally, Quantbot Technologies LP acquired a new position in shares of AxoGen during the third quarter valued at $165,000. Institutional investors own 80.29% of the company's stock.
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
See Also
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
